Delving into the Latest Updates on BTG-1675A with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Anxiety DisordersDepressive Disorder

Originator Organization

BTG International Ltd.

Active Organization-

Inactive Organization

BTG International Ltd.

Abiogen Pharma SpA

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H15NO3

InChIKeyFGCXTWWWHFWHEA-UHFFFAOYSA-N

CAS Registry812639-72-8

OBJECTIVEThe aim of the present study was to evaluate the anxiolytic properties of the new isoxazoline compounds BTG1640 and BTG1675A in comparison with diazepam.MATERIALS AND METHODSWe evaluated the ultrasonic distress emission in both sexes of neonatal rat pups (which seems to be a sensitive indicator of the rat emotional reactivity and represents a valuable tool to screen compounds with expected anxiolytic properties) and the locomotor activity in 30-day old rat pups.RESULTSWe found a significant reduction in the number of emitted ultrasonic calls only after i.p. administration of diazepam 1 mg/kg, while no significant reduction have been detected after i.p. administration of BTG 1640 and BTG 1675A. Furthermore, we found a significant reduction of locomotor activity in the first 10' of the test, only in the group treated with diazepam 0.1 mg.CONCLUSIONSThe tests validating the supposed anxiolytic properties of the new isoxazoline compounds BTG1640 and BTG1675A, in comparison with diazepam, gave negative results.

100 Deals associated with BTG-1675A

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anxiety Disorders	Phase 1	-	BTG International Ltd.	-
Anxiety Disorders	Phase 1	-	Abiogen Pharma SpA	-
Depressive Disorder	Phase 1	-	BTG International Ltd.	-
Depressive Disorder	Phase 1	-	Abiogen Pharma SpA	-